Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × HER2 Negative Breast Cancer × ribociclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 35 Neoplasm Metastasis 5 Ovarian Neoplasms 2 Neoplasms 2 Endometrial Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Breast Neoplasms, Male 2 Breast Diseases 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Recurrence 1 Neoplasms by Site 1 Lung Neoplasms 1 Locoregional Recurrence 1 Hereditary Sensory and Autonomic Neuropathies 1 Head and Neck Neoplasms 1 HER2 Negative Breast Cancer Not Immediately Operated 1 HER2 Negative Breast Cancer 1 Glioma 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1 ER+ HER2- Advanced Breast Cancer 1 Digestive System Neoplasms 1 Diffuse Intrinsic Pontine Glioma 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

ribociclib 1 Tretinoin 1 Letrozole 1 Goserelin 1 Drug Therapy 1 Chemotherapy, Adjuvant 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06953882 2025-07-14

SELECT

Yale University

Phase 2 Recruiting

HER2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡